Amicus Therapeutics (FOLD) Cost of Revenue (2016 - 2025)
Historic Cost of Revenue for Amicus Therapeutics (FOLD) over the last 10 years, with Q3 2025 value amounting to $19.5 million.
- Amicus Therapeutics' Cost of Revenue rose 4659.99% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.2 million, marking a year-over-year increase of 2384.54%. This contributed to the annual value of $52.9 million for FY2024, which is 4183.95% up from last year.
- Amicus Therapeutics' Cost of Revenue amounted to $19.5 million in Q3 2025, which was up 4659.99% from $15.2 million recorded in Q2 2025.
- In the past 5 years, Amicus Therapeutics' Cost of Revenue registered a high of $19.5 million during Q3 2025, and its lowest value of $6.5 million during Q1 2021.
- In the last 5 years, Amicus Therapeutics' Cost of Revenue had a median value of $11.3 million in 2024 and averaged $11.0 million.
- As far as peak fluctuations go, Amicus Therapeutics' Cost of Revenue crashed by 2597.5% in 2023, and later surged by 9543.36% in 2024.
- Over the past 5 years, Amicus Therapeutics' Cost of Revenue (Quarter) stood at $7.9 million in 2021, then increased by 19.53% to $9.4 million in 2022, then grew by 20.67% to $11.3 million in 2023, then skyrocketed by 31.01% to $14.8 million in 2024, then soared by 31.21% to $19.5 million in 2025.
- Its last three reported values are $19.5 million in Q3 2025, $15.2 million for Q2 2025, and $11.7 million during Q1 2025.